CN2824949Y - An in-vitro molecule-absorbing circulating system - Google Patents
An in-vitro molecule-absorbing circulating system Download PDFInfo
- Publication number
- CN2824949Y CN2824949Y CN 200520103051 CN200520103051U CN2824949Y CN 2824949 Y CN2824949 Y CN 2824949Y CN 200520103051 CN200520103051 CN 200520103051 CN 200520103051 U CN200520103051 U CN 200520103051U CN 2824949 Y CN2824949 Y CN 2824949Y
- Authority
- CN
- China
- Prior art keywords
- membrane
- dialyser
- albumin
- blood
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model relates to an in-vitro molecule adsorbing circulating system comprising an in-vitro blood circulating line and an albumin liquid circulating line. The in-vitro blood circulating line comprises a blood pump and an intelligent dialyzer, wherein simulating membranes which have selectivity for protein binding toxins and water-soluble toxins are arranged in the intelligent dialyzer. The simulating membranes are hollow fiber membranes which have the structural parameters that the thickness of each membrane wall is 10 to 30 mum; the total surface area of each membrane is 2.1 to 2.4 m< 2 >; the hole diameter of each hole on the membranes allows molecules with the molecular weight of 60000 daltons to 66000 daltons to pass through. The utility model has the advantages that the wall thickness is controlled within a reasonable range so that the rate of rupture of membrane is decreased, the hole diameter of each hole on the simulating membranes is controlled within a reasonable range so that the treatment time can be shortened, the usage amount of anticoagulant is decreased so that the bleeding risk is reduced and the membrane surface area of each simulating membrane is controlled within a reasonable range by using a reasonable mathematical model so that the performance of membrane separation is favorable.
Description
(1) technical field
This utility model relates to a kind of armarium, and a kind of external molecular adsorption and circulation system relates in particular to the external artificial liver support system that can remove protein binding toxin and water solublity toxin, temporary alternative human liver's function simultaneously.
(2) background technology
In the liver failure, because of the liver detoxification function deficiency, a large amount of protein binding toxins and water solublity toxin are accumulated in blood samples of patients.Using present medical science isolation technics can separate the water solublity toxin, yet with the bonded protein binding toxin of part mode, common blood purification method can't carry out selective and removing effectively to it.
Clinical data proves, protein binding toxin can cause multiple endogenous and external source toxic reaction in the human body, and therefore, it is extremely urgent to develop a kind of artificial liver support system of protein binding toxin and water solublity toxin of removing simultaneously in the blood.
The following dual mode of the general employing of existing artificial liver support system:
1, abiotic type artificial liver support system
The type artificial liver support system is that the means such as plasmapheresis, blood/plasma perfusion and hemodialysis by routine are removed the septicemia element, reaches to alleviate burden of liver, regenerated liver cell to recover the purpose of liver function.
Plasmapheresis: be to replace the blood plasma that patient's body includes toxin, make blood purification to reach the purpose of artificial liver treatment with healthy donors blood plasma.This artificial liver support system mainly is made up of blood constituent separator, blood pump and blood access.During treatment, the input port is connected with the patient vessel with delivery outlet, blood samples of patients is drawn in body, by blood constituent separator separated plasma and cell component, after discarding band toxenia slurry, cell component, additional albumin, donor blood plasma and balance liquid etc. are fed back in the bodies, thereby blood samples of patients is purified, realize artificial liver antidotal purpose.The shortcoming of plasmapheresis is that side effect is big, and the antidotal therapy effect is limited, and use can abandon many materials to the human body beneficial in the blood plasma separately, and is big to the demand of healthy donors blood plasma, causes waste etc.; And most of protein binding toxin not only is present in the blood plasma, also is distributed in simultaneously in the tissue, and behind the plasmapheresis, toxin is very fast to distribute in fresh plasma again.
The blood/plasma perfusion: i.e. blood absorption, remove the septicemia element by the extracorporeal circulation adsorber, make blood purification to reach the purpose of artificial liver treatment.This artificial liver support system mainly is made up of adsorber, blood pump and blood access.During treatment, the input port is connected with the patient vessel with delivery outlet, and blood samples of patients is drawn in body, utilizes materials such as active carbon in the adsorber, ion exchange resin that the septicemia element is carried out adsorption cleaning, realizes artificial liver antidotal purpose.The shortcoming of blood/plasma perfusion is can not active adsorption micromolecule toxin, and active carbon is very poor to the protein binding toxin absorbability.Except that toxicant is eliminated, also remove some hepatocyte growth factors and hormone.If the biocompatibility of adsorbent is poor, also can causes complement system to activate and cause system's inflammatory reaction.
Hemodialysis: be by a kind of special semipermeable membrane selective clearing septicemia element, make blood purification to reach the purpose of artificial liver treatment.This artificial liver support system mainly is made up of dialyser, blood pump and blood access.During treatment, the input port is connected with the patient vessel with delivery outlet, and blood samples of patients is drawn in body, utilizes the semipermeable membrane in the dialyser that the septicemia element is separated, and realizes artificial liver antidotal purpose.The shortcoming of hemodialysis is that protein binding toxin often carries out height with the albumin molecule of non-permeability and combines, and therefore can not obviously see through dialyzer and enter dialysis solution.
2, the Biotype artificial rami hepatici is held system
The type artificial liver support system is that blood samples of patients is drawn in body, interior tube chamber perfect aspect outer circulation by a bioreactor, use semipermeable membrane to carry out the exchange of medium and small material in the cyclic process, and utilize that the exogenous hepatocyte cultivated at interior wall of the lumen is synthesized, functions such as detoxifcation and biotransformation, to reach the purpose of artificial liver treatment.The shortcoming of Biotype artificial liver is that the exogenous hepatocyte of In vitro culture can cause the allosome rejection, and alternative human liver is limited in one's ability, present stage clinical effectiveness still undesirable, the expense costliness.
International patent is that WO 94/21363 international monopoly has proposed a kind of so external artificial liver support system, removes protein binding toxin by analogue membrane, use dialysis solution albumin.This patent to the description of analogue membrane is: film must meet following three conditions:
1. wall thickness is enough thin, must preferably less than 1 micron, or even be lower than 0.1 micron and 0.01 micron less than 5 microns.
2. film upper channel aperture is enough big, and unwanted molecule must be able to pass through smoothly; Must also be enough little simultaneously, albumen among the prevention protein solution A and the PBS receptor protein among the dialysis solution B pass through.When blood and blood plasma were dialysed as protein solution, passage can be 66000 dalton by the molecular weight upper limit, and reasonable memebrane protein transmitance should be controlled at below 0.1, and outstanding film is below 0.01.
3. the chemistry of protein solution A side form and physical arrangement guarantee that unnecessary material passes through, possible principle have hydrophilic or hydrophobic domains relevant.
But clinical experiment shows: even be under 5 microns the situation at wall thickness, the rupture of membranes rate still can be about 30%, well imagines at wall thickness to be lower than 1 micron even be lower than under the situation of 0.1 micron and 0.01 micron, and the rupture of membranes rate also can be higher.But the too thick removal effect that can influence toxin again of wall thickness, so wall thickness must be determined in a suitable scope.
This patent can not cause determining the separating property of film to be described as " passage can be 66000 dalton by the molecular weight upper limit " in passage aperture by the lower limit of molecular weight and clearly propose passage.In fact passage can also be very important by the definite of lower molecular weight limits in the practical operation, and lower limit should make protein binding toxin can pass through passage smoothly.
This patent does not provide definition to membrane area yet, and membrane area is very large to the influence of separating property.
(3) summary of the invention
For the analogue membrane rupture of membranes rate height that overcomes external artificial liver support system use in the prior art, the separation property of film do not have the deficiency of reasonable definition, this utility model that the external artificial liver support system that a kind of analogue membrane rupture of membranes rate separation property low, film defines in the reasonable scope, the toxin separating property is good is provided.
The technical scheme in the invention for solving the technical problem is:
A kind of external molecular adsorption and circulation system comprises extracorporeal circulation of blood pipeline, albumin liquid circulation line;
Comprise blood pump, intelligent dialyser on the described extracorporeal circulation of blood pipeline, be provided with in the described intelligent dialyser protein binding toxin and water solublity toxin are had optionally analogue membrane, described analogue membrane is separated into extracorporeal circulation of blood pipeline side and albumin liquid circulation pipe trackside with described intelligent dialyser, intelligent dialyser described here is the high flux dialyser, and described analogue membrane is the selectivity semipermeable membrane;
Comprise albumin liquid pump, toxin adsorber on the described albumin liquid circulation line, be furnished with the dialysis solution albumin in the described albumin liquid circulation line;
The input of described albumin liquid circulation line and outfan all are connected on the described intelligent dialyser; Described analogue membrane is a hollow-fibre membrane, and its structural parameters are as follows: membranous wall is thick: 10-30 μ m, film total surface area: 2.1-2.4m
2, the aperture in hole on the film: allowing molecular weight is that 60000 dalton-66000 dalton passes through with interior molecule.Be provided with many hollow-fibre membranes in the common intelligent dialyser, changeable, can be coarse to fine, said here film total surface area is meant the summation of the effective hollow-fibre membrane membrane area of each root in the intelligent dialyser.
Further, also comprise tremulous pulse kettle, vein kettle and bubble monitor on the described extracorporeal circulation of blood pipeline; Also comprise blood leakage monitor, bubble trap on the described albumin circulation line.
Further, also be provided with the small throughput dialyser on the albumin liquid circulation line between described bubble trap and the toxin adsorber, described small throughput dialyser connects dialysis machine by the liquid pipe, described dialysis machine and described small throughput dialyser and the liquid pipe that is connected both constitute the dialysis solution circulation line, are furnished with dialysis solution in the described dialysis solution circulation line;
Be provided with in the described small throughput dialyser water solublity toxin is had optionally dialyzer, described dialyzer is separated into albumin liquid circulation pipe trackside and dialysis solution circulation pipe trackside with described small throughput dialyser.
During concrete the application, can be used as external artificial liver support system and use, comprise extracorporeal circulation of blood pipeline, albumin liquid circulation line, blood of human body is in circulation in the extracorporeal circulation of blood pipeline, and the dialysis solution albumin of preparation is in circulation in the albumin liquid circulation line; Be furnished with tremulous pulse outfan, blood pump 1, tremulous pulse kettle 2, intelligent dialyser 3, vein kettle 4, bubble monitor 5 and vein input on the described extracorporeal circulation of blood pipeline successively, be provided with in the described intelligent dialyser 3 protein binding toxin and water solublity toxin are had optionally analogue membrane, described analogue membrane is separated into extracorporeal circulation of blood pipeline side and albumin liquid circulation pipe trackside with described intelligent dialyser 3;
Arrange albumin outfan, blood leakage monitor 6, albumin liquid pump 7, bubble trap 8, small throughput dialyser 9, toxin adsorber successively on the described albumin liquid circulation line, this toxin adsorber comprises adsorber 10 and filter 11; Described adsorber 10 is active carbon adsorption column or anion exchange adsorption column.
Further, described hollow-fibre membrane wall thickness: 15-20 μ m, film total surface area: 2.4m
2
By external molecular adsorption and circulation system described in the utility model (especially as artificial liver support system), most protein binding toxin and the analogue membrane of water solublity toxin in intelligent dialyser enter albumin liquid circulation line with diffusion way in the blood samples of patients, and albumin in the blood and various benefit materials then are retained and can not lose.Here, the dialysis solution albumin in the albumin liquid circulation line has played the effect of particular molecule adsorbent, combines protein binding toxin in the blood with competitive way; By the albumin liquid circulation line of this artificial liver support system, the dialyzer of water solublity toxin in the small throughput dialyser in the dialysis solution albumin enters the dialysis solution circulation line with diffusion way.Toxin in the dialysis solution albumin is adsorbed purification through the toxin adsorber.At this moment, the dialysis solution albumin has been finished regenerative process, and the dialysis solution albumin inlet that is introduced into intelligent dialyser is to carry out new circulation; Dialysis solution circulation line by this external molecular adsorption and circulation system, the dialysis solution that contains the water solublity toxin is discarded by the collection of conventional dialysis machine, will inject the dialysis solution inlet of small throughput dialyser to carry out new circulation through the equilibrated fresh dialysis fluid of electrolyte, glucose and pH simultaneously.
The beneficial effects of the utility model are: 1. wall thickness is controlled in the reasonable range and does not influence the toxin separating effect, greatly reduces the rupture of membranes rate.2. the aperture in hole is controlled in the reasonable range on the analogue membrane, realizes the high flux of toxin as far as possible, can shorten treatment time (need 6-8 hour usually, and use this utility model only to need 5 hours), alleviate patient's misery.When blood during for a long time in extracorporeal circulation in order to prevent condensing of blood, must add anticoagulant, and the use of anticoagulant can increase patient's danger of bleeding, this utility model is because treatment time has been shortened in the change of film properties, reduce the use amount of anticoagulant, thereby reduced hemorrhage risk.4. the membrane area of analogue membrane adopts rational mathematical model control in the reasonable scope, and membrane separating property is good.
(4) description of drawings
Fig. 1 is embodiment one a described structural representation of the present utility model.
Fig. 2 is embodiment one described this utility model extracorporeal circulation of blood pipeline side human albumin changes of contents figure in time and and uses the effect of Fresenius to contrast.
Fig. 3 is embodiment one described this utility model extracorporeal circulation of blood pipeline side unconjugated bilirubin changes of contents figure in time and and uses the effect of Fresenius to contrast.
Fig. 4 is embodiment one described this utility model extracorporeal circulation of blood pipeline side bromine sulphur phenol sodium changes of contents figure in time and and uses the effect of Fresenius to contrast.
Fig. 5 is embodiment one described this utility model extracorporeal circulation of blood pipeline side phenol changes of contents figure in time and and uses the effect of Fresenius to contrast.
Fig. 6 is embodiment one described this utility model extracorporeal circulation of blood pipeline side free fatty changes of contents figure in time and and uses the effect of Fresenius to contrast.
Fig. 7 is embodiment two described this utility model.
Fig. 8-the 12nd, the effect contrast figure of embodiment two described this utility model and use Fresenius.
Figure 13-the 17th, the effect contrast figure of embodiment three described this utility model and use Fresenius.
Figure 18-the 22nd, the effect contrast figure of embodiment four described this utility model and use Fresenius.
Figure 23-the 27th, the effect contrast figure of embodiment five described this utility model and use Fresenius.
Figure 28-the 32nd, the effect contrast figure of embodiment six described this utility model and use Fresenius.
(5) specific embodiment
Below in conjunction with the drawings and specific embodiments this utility model is described in further detail.
Embodiment one
With reference to Fig. 1, a kind of external molecular adsorption and circulation system uses as external artificial liver support system, comprises extracorporeal circulation of blood pipeline, albumin liquid circulation line, blood of human body is in circulation in the extracorporeal circulation of blood pipeline, and the dialysis solution albumin of preparation is in circulation in the albumin liquid circulation line;
Be furnished with tremulous pulse outfan, blood pump 1, tremulous pulse kettle 2, intelligent dialyser 3, vein kettle 4, bubble monitor 5 and vein input on the described extracorporeal circulation of blood pipeline successively, be provided with in the described intelligent dialyser 3 protein binding toxin and water solublity toxin are had optionally analogue membrane, described analogue membrane is separated into extracorporeal circulation of blood pipeline side and albumin liquid circulation pipe trackside with described intelligent dialyser 3.Intelligent dialyser 3 described here is the high flux dialyser, and described analogue membrane is the selectivity semipermeable membrane;
Arrange albumin outfan, blood leakage monitor 6, albumin liquid pump 7, bubble trap 8, small throughput dialyser 9, toxin adsorber successively on the described albumin liquid circulation line, this toxin adsorber comprises adsorber 10 and filter 11; Described adsorber 10 is active carbon adsorption column or anion exchange adsorption column, in general, active carbon adsorption column adopts hemoperfusion level medical activated carbon to fill out post, column volume is 250ml or 350ml, at present business-like product such as the YTS series disposable blood perfusion device of Ai Er blood purification equipment factory and ADSORBA 250, the ADSORBA 350 etc. of Zinpro Corp.; The anion exchange adsorption column adopts quaternary ammonium type anion type polystyrene-divinylbenzene resin to fill out post, column volume is 250ml or 350ml, and business-like product has the HA series blood perfusion device of beautiful pearl biomaterial for medical purpose company limited and the BRS 350 of rising sun medical company etc. at present.
The input of described albumin liquid circulation line and outfan all are connected on the described intelligent dialyser 3;
Described analogue membrane is a hollow-fibre membrane, and its structural parameters are as follows: membranous wall is thick: 20 μ m, film total surface area: 2.4m
2, the aperture in hole on the film: allowing molecular weight is that 60000 dalton molecules pass through.(molecular weight of protein binding toxin bigger be about 50000 dalton, and the molecular weight of the molecular weight ratio protein binding toxin of water solublity toxin is much smaller, can pass through analogue membrane as long as guarantee protein binding toxin here, just can guarantee the water solublity toxin by)
In the present embodiment, the length of single hollow-fibre membrane is 30cm, and the film internal diameter of single hollow-fibre membrane is 200 μ m, and the film external diameter is 240 μ m, the girth that can draw single hollow-fibre membrane like this is 0.000754m, and the surface area of single hollow-fibre membrane is 0.000226m
2, reach 2.4m in order to make total surface area
2, present embodiment needs 10610 hollow-fibre membranes.
Described small throughput dialyser 9 connects dialysis machine 12 by the liquid pipe, and described dialysis machine 12 and described small throughput dialyser 9 and the liquid pipe that is connected both constitute the dialysis solution circulation line, and the dialysis solution for preparing in the dialysis solution circulation line is in circulation; Be provided with in the described small throughput dialyser 9 the water solublity toxin is had optionally dialyzer, described dialyzer is separated into albumin liquid circulation pipe trackside and dialysis solution circulation pipe trackside with described small throughput dialyser 9.The commercialization fully of small throughput dialyser, the F8 of existing product such as Fresenius company, the Polyflux 6L of Zinpro Corp., BLS 512 G that Bel restrains company and CA 210 G of hundred special companies can use wherein.
By the described artificial liver support system of present embodiment, most protein binding toxin and the water solublity toxin analogue membrane in intelligent dialyser 3 enters albumin liquid circulation line with diffusion way in the receptor blood, and albumin in the blood and various benefit materials then are retained and can not lose.Here, the dialysis solution albumin in the albumin liquid circulation line has played the effect of particular molecule adsorbent, combines protein binding toxin in the blood with competitive way; By the dialysis solution circulation line of this artificial liver support system, the dialyzer of water solublity toxin in small throughput dialyser 9 in the dialysis solution albumin is adsorbed purification with the toxin that diffusion way enters in dialysis solution circulation line, the dialysis solution albumin through toxin adsorber 10, filter 11.At this moment, the dialysis solution albumin has been finished regenerative process, and the dialysis solution albumin inlet that is introduced into intelligent dialyser 3 is to carry out new circulation; Dialysis solution circulation line by this artificial liver support system, the dialysis solution that contains the water solublity toxin is discarded by the collection of conventional dialysis machine, will inject the dialysis solution inlet of small throughput dialyser 9 to carry out new circulation through the equilibrated fresh dialysis fluid of electrolyte, glucose and pH simultaneously.
The specific operation process of present embodiment is:
1, energized;
2, pipeline is connected receptor;
3, the use priming fluid is carried out preliminary filling, pre-charging time 15min, 20 ℃ of preliminary filling temperature to the analogue membrane of intelligent dialyser 3;
4, blood plasma simulated solution flow velocity being set is 150ml/min, and dialysis solution albumin flow velocity is 150ml/min, and dialysate flow rate is 150ml/min.The extracorporeal circulation of blood pipeline is provided with calparine cap, suitably replenishes heparin in case Trostin M according to the individual variation of receptor.
5, open the extracorporeal circulation of blood pipeline, carry out blood priming by product specification; Open albumin liquid circulation line and dialysis solution circulation line, carry out the separating of protein binding toxin and water solublity toxin in the blood, removing;
6, the single operation cycle is 90min, shuts down back disconnection pipeline and is connected with the receptor venous;
7, human albumin in the collection blood plasma simulated solution and protein binding toxin are with the concentration data of treatment time variation.
Prepare towards liquid in advance in the present embodiment: dissolving is stand-by after adding a certain amount of human serum albumin in the NaCl solution of 0.9wt%.Albumin concentration generally is controlled in 1～50g/100ml, and preferred concentration is 6～40g/100ml, and optium concentration is 8～30mg/100ml.Step is as follows: 9g sodium chloride is dissolved in the 1000ml redistilled water, adds 100g human serum albumin dissolving again.
Blood plasma simulated solution preparation in the present embodiment: add following concentration of analog protein binding toxin material in normal, young, the healthy male donor blood plasma, to reach high protein in conjunction with the toxin concentration level:
Unconjugated bilirubin 110mg/l
Bromine sulphur phenol sodium 230mg/l
Phenol 530mg/l
Free fatty (sad) 750mg/l
Step is as follows: in the sad NaOH solution that is dissolved in 50ml 0.1mol/l of 110mg unconjugated bilirubin, 230mg bromine sulphur phenol sodium, 530mg phenol and 750mg, add (the defat of 2.5g human albumin again, Sigma company) also dissolving is regulated pH to 7.4 with the acetic acid of 30wt%; Subsequently above-mentioned 50ml solution is added in the 950ml healthy donors blood plasma.
Add the protein binding toxin receptor protein in the present embodiment in the NaCl solution of the albuminous preparation of dialysis solution: 0.9wt%, this utility model receptor protein is the human serum albumin, in general, albuminous concentration range is 1～50g/100ml, preferred concentration is 6～40g/100ml, better concentration is 8～30g/100ml, and optium concentration is 8～20g/100ml.Also contain other components in this utility model dialysis solution albumin, as NaCl, KCl, MgCl
2, CaCl
2, sodium lactate and glucose etc., carry out suitable adjustment according to the electrolysis situation in the different blood samples of patients.In general, the ion concentration scope and the preferred concentration of above-mentioned each component are respectively:
Na
+Preferable 135～the 140mmol/l of general 130～145mmol/l
Ca
2+Preferable 1.5～the 2.0mmol/l of general 1.0～2.5mmol/l
K
+Preferable 3.0～the 3.5mmol/l of general 2.0～4.0mmol/l
Mg
2+Preferable 0.4～the 0.6mmol/l of general 0.2～0.8mmol/l
Cl
-Preferable 104～the 108mmol/l of general 100～110mmol/l
COOH
-Preferable 33～the 38mmol/l of general 30～40mmol/l
It below is an albuminous proportioning example of dialysis solution: contain in every liter of dialysis solution albumin: the single water glucose of the serum albumin of human plasma 10～20% (w/v), 6.10g sodium chloride, 4.00g sodium acetate, 0.15g potassium chloride, 0.31g calcium chloride dihydrate, 0.15g magnesium chloride hexahydrate and 1.65g.
The preparation of dialysis solution in the present embodiment: this utility model dialysis solution is a bicarbonate buffer, can remove the water solublity toxin that enters albumin liquid circulation line simultaneously, realizes the albuminous preliminary regeneration of dialysis solution.This utility model bicarbonate buffer is formulated according to a certain ratio by sodium carbonate and sodium bicarbonate.In general, the ion concentration scope and the preferred concentration of above-mentioned each component are respectively:
Na
+Preferable 1.1～the 1.5mmol/l of general 1.1～1.9mmol/l
CO
3 2-Preferable 0.1～the 0.5mmol/l of general 0.1～0.9mmol/l
HCO
3 -Preferable 0.5～the 0.9mmol/l of general 0.1～0.9mmol/l
Below be the proportioning example of a bicarbonate buffer: contain 85.86g washing soda and 58.80g sodium bicarbonate in every liter of bicarbonate buffer.
With reference to Fig. 2-6, under identical experiment condition, effect obviously was inferior to the described external artificial liver support system of present embodiment when the intelligence dialyser adopted the HF 80 of Fresenius company: as seen from Figure 2, after adopting the described analogue membrane of present embodiment, what do not take place and change in albuminous rejection, and by Fig. 3-4 as can be seen, the clearance of all kinds of protein binding toxins is greatly improved.
The major product information of Fresenius HF 80 is as follows:
| Model | Wall thickness μ m | Surface area m 2 | Blood priming ml | Ultrafiltrate coefficient ml/h/mmHg | Membrane material | |
| HF | ||||||
| 80 | 40 | 1 | 110 | 55 | Polysulfones | Oxirane |
Embodiment two
With reference to Fig. 7, a kind of external artificial liver support system comprises extracorporeal circulation of blood pipeline, albumin liquid circulation line;
Be furnished with blood pump 1, tremulous pulse kettle 2, intelligent dialyser 3, vein kettle 4 and bubble monitor 5 on the described extracorporeal circulation of blood pipeline successively, be provided with in the described intelligent dialyser 2 protein binding toxin and water solublity toxin are had optionally analogue membrane, described analogue membrane is separated into extracorporeal circulation of blood pipeline side and albumin liquid circulation pipe trackside with described intelligent dialyser 3, intelligent dialyser 3 described here is the high flux dialyser, and described analogue membrane is the selectivity semipermeable membrane;
Arrange successively on the described albumin liquid circulation line that blood leakage monitor 6, albumin liquid pump 7, bubble trap 8, this toxin adsorber of toxin adsorber comprise adsorber 10 and filter 11;
The input of described albumin liquid circulation line and outfan all are connected on the described intelligent dialyser 3;
Described analogue membrane is a hollow-fibre membrane, and its structural parameters are as follows: membranous wall is thick: 30 μ m, film total surface area: 2.1m
2, the aperture in hole on the film: allowing molecular weight is that 64000 daltonian molecules pass through.
In the present embodiment, the length of single hollow-fibre membrane is 25cm, and the film internal diameter of single hollow-fibre membrane is 200 μ m, and the film external diameter is 260 μ m, the girth that can draw single hollow-fibre membrane like this is 0.000817m, and the surface area of single hollow-fibre membrane is 0.000204m
2, reach 2.1m in order to make total surface area
2, present embodiment needs 10283 hollow-fibre membranes.
All the other structures, embodiment and element are selected identical with embodiment one.
With reference to Fig. 8-12, under identical experiment condition, effect obviously was inferior to the described external artificial liver support system of present embodiment when the intelligence dialyser adopted the HF 80 of Fresenius company: as seen from Figure 8, after adopting the described analogue membrane of present embodiment, what do not take place and change in albuminous rejection, and by Fig. 9-12 as can be seen, the clearance of all kinds of protein binding toxins is greatly improved.
Present embodiment is compared with embodiment one, has omitted the dialysis solution circulation line, and the water solublity toxin in the albumin liquid circulation line can not obtain highly effective removal like this, and it is poorer than embodiment one that historical facts or anecdotes is executed effect.
Embodiment three
The structural parameters of analogue membrane are as follows: membranous wall is thick: 25 μ m, film total surface area: 2.1m
2, the aperture in hole on the film: allowing molecular weight is that 62000 daltonian molecules pass through.
In the present embodiment, the length of single hollow-fibre membrane is 30cm, and the film internal diameter of single hollow-fibre membrane is 200 μ m, and the film external diameter is 250 μ m, the girth that can draw single hollow-fibre membrane like this is 0.000785m, and the surface area of single hollow-fibre membrane is 0.000236m
2, reach 2.1m in order to make total surface area
2, present embodiment needs 8912 hollow-fibre membranes.
With reference to Figure 13-17, under identical experiment condition, effect obviously was inferior to the described external artificial liver support system of present embodiment when the intelligence dialyser adopted the HF 80 of Fresenius company: as seen from Figure 13, after adopting the described analogue membrane of present embodiment, what do not take place and change in albuminous rejection, and by Figure 14-17 as can be seen, the clearance of all kinds of protein binding toxins is greatly improved.
All the other structures, embodiment and element are selected identical with embodiment one.
Embodiment four
The structural parameters of analogue membrane are as follows: membranous wall is thick: 25 μ m, film total surface area: 2.3m
2, the aperture in hole on the film: allowing molecular weight is that 60000 daltonian molecules pass through.
In the present embodiment, the length of single hollow-fibre membrane is 35cm, and the film internal diameter of single hollow-fibre membrane is 200 μ m, and the film external diameter is 250 μ m, the girth that can draw single hollow-fibre membrane like this is 0.000785m, and the surface area of single hollow-fibre membrane is 0.000275m
2, reach 2.3m in order to make total surface area
2, present embodiment needs 8367 hollow-fibre membranes.
With reference to Figure 18-22, under identical experiment condition, effect obviously was inferior to the described external artificial liver support system of present embodiment when the intelligence dialyser adopted the HF 80 of Fresenius company: as seen from Figure 18, after adopting the described analogue membrane of present embodiment, what do not take place and change in albuminous rejection, and by Figure 19-22 as can be seen, the clearance of all kinds of protein binding toxins is greatly improved.
All the other structures, embodiment and element are selected identical with embodiment one.
Embodiment five
The structural parameters of analogue membrane are as follows: membranous wall is thick: 30 μ m, film total surface area: 2.4m
2, the aperture in hole on the film: allowing molecular weight is that 60000 daltonian molecules pass through.
In the present embodiment, the length of single hollow-fibre membrane is 25cm, and the film internal diameter of single hollow-fibre membrane is 200 μ m, and the film external diameter is 260 μ m, the girth that can draw single hollow-fibre membrane like this is 0.000817m, and the surface area of single hollow-fibre membrane is 0.000204m
2, reach 2.4m in order to make total surface area
2, present embodiment needs 11753 hollow-fibre membranes.
With reference to Figure 23-27, under identical experiment condition, effect obviously was inferior to the described external artificial liver support system of present embodiment when the intelligence dialyser adopted the HF 80 of Fresenius company: as seen from Figure 23, after adopting the described analogue membrane of present embodiment, what do not take place and change in albuminous rejection, and by Figure 24-27 as can be seen, the clearance of all kinds of protein binding toxins is greatly improved.
All the other structures, embodiment and element are selected identical with embodiment one.
Embodiment six
The structural parameters of analogue membrane are as follows: membranous wall is thick: 20 μ m, film total surface area: 2.3m
2, the aperture in hole on the film: allowing molecular weight is that 64000 daltonian molecules pass through.
In the present embodiment, the length of single hollow-fibre membrane is 30cm, and the film internal diameter of single hollow-fibre membrane is 200 μ m, and the film external diameter is 240 μ m, the girth that can draw single hollow-fibre membrane like this is 0.000754m, and the surface area of single hollow-fibre membrane is 0.000226m
2, reach 2.3m in order to make total surface area
2, present embodiment needs 10168 hollow-fibre membranes.
With reference to Figure 28-32, under identical experiment condition, effect obviously was inferior to the described external artificial liver support system of present embodiment when the intelligence dialyser adopted the HF 80 of Fresenius company: as seen from Figure 28, after adopting the described analogue membrane of present embodiment, what do not take place and change in albuminous rejection, and by Figure 29-32 as can be seen, the clearance of all kinds of protein binding toxins is greatly improved.
All the other structures, embodiment and element are selected identical with embodiment one.
Claims (4)
1. an external molecular adsorption and circulation system comprises extracorporeal circulation of blood pipeline, albumin liquid circulation line;
Comprise blood pump, intelligent dialyser on the described extracorporeal circulation of blood pipeline, be provided with in the described intelligent dialyser protein binding toxin and water solublity toxin are had optionally analogue membrane, described analogue membrane is separated into extracorporeal circulation of blood pipeline side and albumin liquid circulation pipe trackside with described intelligent dialyser;
Comprise albumin liquid pump, toxin adsorber on the described albumin liquid circulation line, be furnished with the dialysis solution albumin in the described albumin liquid circulation line;
The input of described albumin liquid circulation line and outfan all are connected on the described intelligent dialyser;
It is characterized in that: described analogue membrane is a hollow-fibre membrane, and its structural parameters are as follows: membranous wall is thick: 10-30 μ m, film total surface area: 2.1-2.4m
2, the aperture in hole on the film: allowing molecular weight is that 60000 dalton-66000 dalton passes through with interior molecule.
2. external molecular adsorption and circulation system as claimed in claim 1 is characterized in that: also comprise tremulous pulse kettle, vein kettle and bubble monitor on the described extracorporeal circulation of blood pipeline; Also comprise blood leakage monitor, bubble trap on the described albumin circulation line.
3. external molecular adsorption and circulation system as claimed in claim 2, it is characterized in that: also be provided with the small throughput dialyser on the albumin liquid circulation line between described bubble trap and the toxin adsorber, described small throughput dialyser connects dialysis machine by the liquid pipe, described dialysis machine and described small throughput dialyser and the liquid pipe that is connected both constitute the dialysis solution circulation line, are furnished with dialysis solution in the described dialysis solution circulation line;
Be provided with in the described small throughput dialyser water solublity toxin is had optionally dialyzer, described dialyzer is separated into albumin liquid circulation pipe trackside and dialysis solution circulation pipe trackside with described small throughput dialyser.
4. external molecular adsorption and circulation system as claimed in claim 3 is characterized in that: the structural parameters of described analogue membrane are: membranous wall is thick: 15-20 μ m, film total surface area: 2.4m
2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200520103051 CN2824949Y (en) | 2005-06-17 | 2005-06-17 | An in-vitro molecule-absorbing circulating system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200520103051 CN2824949Y (en) | 2005-06-17 | 2005-06-17 | An in-vitro molecule-absorbing circulating system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2824949Y true CN2824949Y (en) | 2006-10-11 |
Family
ID=37065132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200520103051 Expired - Lifetime CN2824949Y (en) | 2005-06-17 | 2005-06-17 | An in-vitro molecule-absorbing circulating system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2824949Y (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108472425A (en) * | 2015-12-30 | 2018-08-31 | 费森尤斯医疗保健集团 | It can be used for the cartridge systems of cleaning dialysis solutions |
| CN109069719A (en) * | 2016-03-14 | 2018-12-21 | Hepa净化有限公司 | System or equipment and method for dialysing |
| CN115445438A (en) * | 2014-02-06 | 2022-12-09 | 甘布罗伦迪亚股份公司 | Hemodialyzer for blood purification |
-
2005
- 2005-06-17 CN CN 200520103051 patent/CN2824949Y/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115445438A (en) * | 2014-02-06 | 2022-12-09 | 甘布罗伦迪亚股份公司 | Hemodialyzer for blood purification |
| CN108472425A (en) * | 2015-12-30 | 2018-08-31 | 费森尤斯医疗保健集团 | It can be used for the cartridge systems of cleaning dialysis solutions |
| CN108472425B (en) * | 2015-12-30 | 2021-06-01 | 费森尤斯医疗保健集团 | Cartridge system useful for cleaning dialysis solutions |
| CN109069719A (en) * | 2016-03-14 | 2018-12-21 | Hepa净化有限公司 | System or equipment and method for dialysing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1071585C (en) | Hemofiltration and Plasmafiltration device and methods | |
| JP3486190B2 (en) | Membrane and method for separating protein-binding substance from protein-containing liquid by dialysis | |
| CN105120913B (en) | Sodium and buffer solution source capsule for the controlled compatible stream of modularization | |
| CN105025951B (en) | For the system and method for multi-functional volume fluid control | |
| CN1147304C (en) | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy | |
| US8926543B2 (en) | Immunoactivation blood perfusion filter for the treatment of malignant tumors | |
| CN1761494A (en) | Blood treatment device and method with selective solute extraction | |
| CN103263704B (en) | Be equipped with the plasmapheresis absorption filtration cleaning system of slurry storing bag | |
| WO1997047337A1 (en) | Method for recovering and regenerating peritoneal dialyzate, apparatus therefor, and attachments thereof | |
| WO2016060209A1 (en) | Body fluid filtration device of hollow fiber membrane type, and method for filtrating protein solution | |
| CN1196688A (en) | Affinity membrane system and method of using same | |
| JP2012507373A (en) | Portable peritoneal dialysis system | |
| CN1487853A (en) | Cartridges useful in cleaning dialysis solutions | |
| Santoro et al. | Liver support systems | |
| EP2558177A1 (en) | Anticoagulant-free dialysis systems and methods | |
| CN101862610A (en) | Absorption film for eliminating bilirubin and preparation method thereof | |
| ES2348189T3 (en) | KIT FOR THE TREATMENT OF DISEASES RELATED TO SYSTEMATIC INFLAMMATION. | |
| CN2810611Y (en) | In-vitro artificial liver support system | |
| CN2824949Y (en) | An in-vitro molecule-absorbing circulating system | |
| CN201123923Y (en) | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome | |
| CN1879900A (en) | In vitro molecular adsorption and circulation system | |
| CN2822644Y (en) | Protein A immunoadsorbent system | |
| Botella et al. | Adsorption in hemodialysis | |
| CN202078582U (en) | Combined in-vitro artificial liver support treatment system | |
| CN109794172B (en) | Preparation method of antibacterial hollow fiber membrane for blood purification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20150617 Granted publication date: 20061011 |